about
Very important pharmacogene summary: thiopurine S-methyltransferaseGlutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapyMutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide TherapyStructural Basis of Substrate Recognition in Thiopurine S -Methyltransferase † ‡Human histamine N-methyltransferase pharmacogenetics: gene resequencing, promoter characterization, and functional studies of a common 5'-flanking region single nucleotide polymorphism (SNP)Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomicsThiopurine pathwayGemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkersThe eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing dataGenetic diversity and function in the human cytosolic sulfotransferases.Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET).Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocolHuman sulfotransferases SULT1C1 and SULT1C2: cDNA characterization, gene cloning, and chromosomal localization.Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics.Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network AntideGenetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.Human 3'-phosphoadenosine 5'-phosphosulfate synthetase: radiochemical enzymatic assay, biochemical properties, and hepatic variation.Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency.Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation.Pharmacogenomics: candidate gene identification, functional validation and mechanisms.Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activityFunctional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme.Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase.Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.Human S-adenosylhomocysteine hydrolase: common gene sequence variation and functional genomic characterization.Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formationHuman nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization.Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 1 (PAPSS1) and PAPSS2: gene cloning, characterization and chromosomal localization.Coprescription of tamoxifen and medications that inhibit CYP2D6.CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model systemMetformin pharmacogenomics: biomarkers to mechanisms.Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies.
P50
Q24601748-09A31B50-70AB-44BC-A622-5701B36E36F3Q24629542-F6F7D21A-6D58-4B89-9532-9750F7FFC703Q27334558-48328817-49DC-4535-940A-9097D744BF90Q27650629-B1A4B737-98B5-4A0D-B286-73EC18A35F77Q28217127-A08CC424-C7B4-4CDD-AC9E-7867400B5E23Q28252663-95431246-6341-401E-8C32-5CAC0C65C83AQ28266295-DA79B9ED-3103-4203-9764-6F76FD2BF6D7Q28471821-46FE4B00-9177-4960-9BFE-199F8B591CD6Q28649714-8F3B917E-429F-4933-AFA1-4B56EB48D5B8Q30355169-98A82E0B-5F48-43DF-BC15-D3ABFE8E79B8Q30418252-BC711C64-7A32-4BA2-9219-C444D92EF395Q30572528-6002800A-1069-4F9B-8F38-03A8C96E6621Q30863607-66FC6440-6483-4E72-8550-E3E34A7FCF7EQ30955177-B4546E94-1431-4B8C-9E70-33B2437EDE0EQ31061376-7638E33B-F108-416A-99F6-108BB0B5D7A5Q31110714-BD4FBF13-2A8F-4F99-B72B-0475E26BBE6DQ31835767-91AE611D-0A6F-4069-B648-965298AAE874Q33334710-BE0BD347-5706-429A-96D0-CAFDEF9E995DQ33372321-3681F915-F53E-4A43-8BA5-D3801B80118DQ33375573-207C0B06-171D-43CA-AB70-237286812B51Q33376153-8B33E2AC-6268-4754-B478-4C347676582DQ33418418-58DD15B1-E103-4318-BA55-3310D32035CDQ33584258-3775E63F-94FB-4515-A984-A9B33AF4C50EQ33595261-E50B6922-70AD-4739-B039-E0DD85E7D59FQ33625656-33519E27-A41D-41B3-A664-43DC3F1B8619Q33636637-EF83443D-52FF-40CC-914E-265D676CAD05Q33637143-4D400A06-856A-4DD5-8896-C44014715086Q33725390-1285A663-88BD-47FD-B302-1B342C9FAEF8Q33726940-A1EAA25F-FDD9-4F57-8A0B-AAA19F430C32Q33793932-E7EF0AAF-1DB7-4A93-9BFF-236C10ECA605Q33818637-87F1D22D-2274-4393-AE6E-38CC5A5320C8Q33844619-53A3889C-A68D-454A-A9DA-6DF736E93A4FQ33858887-31170A7B-FCD2-4476-8EF3-B7EE980C2774Q33872852-D361CFB5-1E9B-4FE9-AF1D-09511FC1B0A3Q33890493-2CDD301F-B6A4-4C8A-876B-9D4923D4C8C8Q33898184-F621276D-6404-4FF0-9B63-500BA42DAAE7Q33940572-1DFE90B5-953E-437B-965D-2AD28D7B5C74Q33959783-69797E8E-D254-4787-A4E5-C58304F70C33Q34065310-6930BDEC-1FEB-4650-BF33-050B9FB771ADQ34104708-739EEEF5-BF39-4C84-915B-53F56BE6892D
P50
name
Richard Weinshilboum
@ast
Richard Weinshilboum
@en
Richard Weinshilboum
@es
Richard Weinshilboum
@nl
type
label
Richard Weinshilboum
@ast
Richard Weinshilboum
@en
Richard Weinshilboum
@es
Richard Weinshilboum
@nl
altLabel
R M Weinshilboum
@en
R Weinshilboum
@en
R. M. Weinshilboum
@en
R. Weinshilboum
@en
Richard M Weinshilboum
@en
Richard M. Weinshilboum
@en
Weinshilboum R
@en
Weinshilboum R. M.
@en
Weinshilboum R.
@en
Weinshilboum RM
@en
prefLabel
Richard Weinshilboum
@ast
Richard Weinshilboum
@en
Richard Weinshilboum
@es
Richard Weinshilboum
@nl